Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer

Basit Öğe Kaydı
dc.contributor.authorPaluch-Shimon, S.
dc.contributor.authorNeven, P.
dc.contributor.authorCicin, I.
dc.contributor.authorJiang, Z.
dc.contributor.authorGoetz, M. P.
dc.contributor.authorShimizu, C.
dc.contributor.authorHuang, C. -S.
dc.date.accessioned2024-06-12T11:23:58Z
dc.date.available2024-06-12T11:23:58Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpage48Sen_US
dc.identifier.issn1424-7860
dc.identifier.issn1424-3997
dc.identifier.startpage48Sen_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26749
dc.identifier.volume152en_US
dc.identifier.wosWOS:000912385900076en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherE M H Swiss Medical Publishers Ltden_US
dc.relation.ispartofSwiss Medical Weeklyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleEfficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast canceren_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu